USP Updates Vulnerable Drug List, Adds Tamiflu and Trulicity Amid Supply Concerns
The United States Pharmacopeia (USP) has revised its list of drugs vulnerable to supply chain disruptions, adding Tamiflu and Trulicity. This update follows an expanded risk assessment that now includes key starting materials (KSMs), which are crucial for the production of active pharmaceutical ingredients. The USP's analysis revealed that 48 of the 100 vulnerable drugs rely on KSMs sourced from a single country, with a significant portion coming from China and India. Despite the availability of these drugs, the USP identified potential supply chain weaknesses that could lead to disruptions. The inclusion of KSM supply in the analysis has influenced which drugs are considered vulnerable, with the USP noting that more than a quarter of the drugs on the list have stable supply based on finished product availability but are still at risk due to upstream vulnerabilities. 
